Global RNAi for Therapeutic Competitive Landscape Professional Research Report 2025

Global RNAi for Therapeutic Competitive Landscape Professional Research Report 2025

Research Summary

RNA interference (RNAi) for therapeutic purposes involves harnessing the natural biological process of RNAi to selectively and precisely regulate gene expression within cells. RNAi is a mechanism where small RNA molecules, such as small interfering RNA (siRNA) or microRNA (miRNA), interfere with the translation or stability of specific messenger RNA (mRNA) molecules, thereby preventing the synthesis of a particular protein. In therapeutic applications, researchers design and deliver synthetic RNA molecules to target and silence disease-associated genes, offering a potential strategy for treating various genetic disorders, viral infections, and certain cancers. RNAi therapeutics aim to exploit this precise gene-silencing mechanism to intervene at the molecular level and correct or mitigate the underlying causes of diseases. While challenges such as effective delivery and off-target effects need to be addressed, RNAi holds significant promise as a novel and targeted approach in the field of personalized medicine and therapeutic development.

According to DIResearch's in-depth investigation and research, the global RNAi for Therapeutic market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.

The major global  manufacturers of RNAi for Therapeutic include Alnylam Pharmaceuticals, Arbutus Biopharma (Tekmira), Arrowhead, Dicerna Pharmaceuticals, Mirna Therapeutics, Quark Pharmaceuticals, RXi Pharmaceuticals, Benitec Biopharma, Silence Therapeutics, Sylentis, miRagen Therapeutics, Gradalis, Sirnaomics, Silenseed etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of RNAi for Therapeutic. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global RNAi for Therapeutic market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the RNAi for Therapeutic market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of RNAi for Therapeutic industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.  

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of RNAi for Therapeutic Include:

Alnylam Pharmaceuticals

Arbutus Biopharma (Tekmira)

Arrowhead

Dicerna Pharmaceuticals

Mirna Therapeutics

Quark Pharmaceuticals

RXi Pharmaceuticals

Benitec Biopharma

Silence Therapeutics

Sylentis

miRagen Therapeutics

Gradalis

Sirnaomics

Silenseed

RNAi for Therapeutic Product Segment Include:

siRNA

miRNA

shRNA

RNAi for Therapeutic Product Application Include:

Cancer

Cardiovascular

HBV

Others

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global RNAi for Therapeutic Industry PESTEL Analysis

Chapter 3: Global RNAi for Therapeutic Industry Porter’s Five Forces Analysis

Chapter 4: Global RNAi for Therapeutic Major Regional Market Size and Forecast Analysis

Chapter 5: Global RNAi for Therapeutic Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Passenger RNAi for Therapeutic Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe RNAi for Therapeutic Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China RNAi for Therapeutic Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) RNAi for Therapeutic Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America RNAi for Therapeutic Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa RNAi for Therapeutic Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global RNAi for Therapeutic Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources